Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in lead programme and to build a world class pioneer factor oncology company  London, 21 November 2019 – Azeria Therapeutics (Azeria), a newly formed pioneer factor […]